#1 Clinical Trials Search in Europe

Denosumab

This article explores the use of denosumab, a medication known by brand names like Xgeva and Prolia, in various clinical trials. These studies aim to assess the drug’s effectiveness, safety profile, and compare it with biosimilar versions across different medical conditions, primarily focusing on bone-related disorders and cancer treatments.

Table of Contents

What is Denosumab?

Denosumab is a medication used to treat various bone-related conditions. It is known by several brand names, including Xgeva[1], Prolia[2], and AMG 162[3]. Denosumab is a type of drug called a monoclonal antibody, which means it’s a laboratory-produced molecule that acts like the antibodies naturally produced by our immune system.

What Conditions Does Denosumab Treat?

Denosumab is used to treat several conditions related to bone health and certain types of cancer:

  • Osteoporosis: A condition where bones become weak and brittle, increasing the risk of fractures[3]
  • Multiple Myeloma: A type of blood cancer that affects plasma cells and can lead to bone damage[4]
  • Bone Metastases: When cancer spreads from its original site to the bones[5]
  • Giant Cell Tumor of Bone (GCTB): A rare, usually non-cancerous tumor that develops in bones[1]
  • Osteogenesis Imperfecta: A genetic disorder characterized by fragile bones that break easily[6]

How Does Denosumab Work?

Denosumab works by targeting a protein called RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). This protein plays a crucial role in the formation and function of cells called osteoclasts, which break down bone tissue. By blocking RANKL, denosumab reduces the activity of osteoclasts, which helps to:[4][6]

  • Increase bone density (make bones stronger)
  • Reduce the risk of fractures
  • Slow down bone damage in cancer patients
  • Inhibit the growth of certain bone tumors

How is Denosumab Administered?

Denosumab is typically administered as a subcutaneous injection, which means it’s injected under the skin. The dosage and frequency of administration can vary depending on the condition being treated:[1][2][3][4][5]

  • For osteoporosis: Usually 60 mg every 6 months
  • For cancer-related conditions: Often 120 mg every 4 weeks
  • For giant cell tumor of bone: 120 mg every 4 weeks, with additional doses on days 8 and 15 of the first month of treatment

The exact dosage and schedule will be determined by your healthcare provider based on your specific condition and needs.

Effectiveness of Denosumab

Clinical trials have shown that denosumab can be effective in treating various bone-related conditions:

  • In postmenopausal women with osteoporosis, denosumab has been shown to increase bone mineral density and reduce the risk of fractures[3]
  • For patients with multiple myeloma, denosumab can help reduce bone-related complications[4]
  • In patients with bone metastases from solid tumors, denosumab can help prevent skeletal-related events (such as fractures or need for radiation therapy)[5]
  • For giant cell tumor of bone, denosumab has shown promising results in reducing tumor size and potentially avoiding the need for extensive surgery[1]

Potential Side Effects

Like all medications, denosumab can cause side effects. Some potential side effects include:[1][2][5]

  • Hypocalcemia: Low levels of calcium in the blood
  • Osteonecrosis of the jaw: A rare but serious condition where the jaw bone is exposed and begins to starve from a lack of blood
  • Injection site reactions
  • Increased risk of infections
  • Muscle and joint pain

It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms you experience while taking denosumab.

Ongoing Research

Research on denosumab is ongoing to further understand its effects and explore its potential in treating other conditions. Some areas of current research include:

  • Comparing the effectiveness of denosumab to other treatments for bone metastases[5]
  • Investigating its use in children with osteogenesis imperfecta[6]
  • Studying different dosages and administration schedules to optimize treatment[3]
  • Evaluating its long-term safety and effectiveness[2]

As research continues, our understanding of denosumab and its potential uses may expand, potentially offering new treatment options for patients with bone-related conditions.

Aspect Details
Study Types Randomized, double-blind, placebo-controlled, dose-response studies
Participants Healthy volunteers, postmenopausal women with osteoporosis, patients with bone metastases from solid tumors
Dosages Tested 14 mg, 35 mg, 60 mg, 100 mg, 120 mg
Administration Subcutaneous injection
Frequency Every 4 weeks or every 6 months, depending on the study
Primary Outcomes Pharmacokinetics, bone mineral density changes, safety profile
Secondary Outcomes Pharmacodynamics, bone turnover markers, immunogenicity
Biosimilars Tested MB09, HLX14, MW032
Study Duration Ranging from 253 days to over 12 months

FAQ

  • What is denosumab and what is it used for? Denosumab is a medication used to treat bone-related conditions. It's commonly used for osteoporosis in postmenopausal women and for preventing skeletal-related events in patients with bone metastases from solid tumors.
  • How is denosumab administered in clinical trials? In the trials, denosumab is typically administered as a subcutaneous injection. The dosage and frequency vary depending on the study, ranging from 14 mg to 120 mg, given every 4 to 6 months.
  • What are biosimilars of denosumab? Biosimilars are highly similar versions of the original biologic drug. In these trials, drugs like MB09, HLX14, and MW032 are being tested as potential biosimilars to denosumab (Xgeva or Prolia).
  • What are the main outcomes measured in these clinical trials? The trials primarily measure pharmacokinetics (how the drug moves through the body), pharmacodynamics (the drug's effects on the body), safety, and efficacy. This includes measuring bone mineral density, bone turnover markers, and monitoring for adverse events.
  • How long do these clinical trials typically last? The duration of these trials varies, but many last for several months to over a year. For example, some trials measure outcomes up to 253 or 274 days after the initial dose.

Ongoing Clinical Trials on Denosumab

  • Study on Denosumab to Prevent Breast Cancer in Women with BRCA1 Mutation

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Spain

  • Study on the Effectiveness of Denosumab with Chemotherapy (Cisplatin, Methotrexate, Doxorubicin) for Patients with Metastatic Osteosarcoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Denosumab Effects on Muscle Strength and Insulin Sensitivity in Patients with Postmenopausal Osteoporosis and Diabetes Mellitus

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Denosumab for Treating Fibrous Dysplasia/McCune-Albright Syndrome in Adults

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Adding Zoledronic Acid or Denosumab to Radiotherapy for Adults with Inoperable Vertebral Bone Metastases

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness of Denosumab for Treating Acute Charcot Foot in Diabetes Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Comparing the effect of romosozumab and denosumab on coronary artery damage in women with postmenopausal osteoporosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Estonia Hungary Latvia Poland Slovakia

  • Study on Treating Osteogenesis Imperfecta in Patients Using Teriparatide and Zoledronic Acid

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Ireland The Netherlands

  • Study Comparing MAB-22 and Denosumab for Treating Osteoporosis in Postmenopausal Women

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Poland

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.
  • Biosimilar: A biologic medical product that is almost an identical copy of an original product manufactured by a different company, aiming to have the same effectiveness and safety profile.
  • Subcutaneous (SC): A method of drug administration where the medication is injected just under the skin.
  • Bone Mineral Density (BMD): A measurement of the amount of calcium and other minerals in a segment of bone, used to diagnose osteoporosis and assess fracture risk.
  • RANKL: Receptor Activator of Nuclear Factor Kappa-B Ligand, a protein involved in bone metabolism that denosumab targets.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body, which is important to assess for biological drugs.
  • Bone Metastases: The spread of cancer to the bone from its original site, which can cause pain and increase the risk of fractures.
  • Osteoporosis: A condition characterized by decreased bone mass and density, increasing the risk of fractures.
  • Anti-drug Antibodies (ADA): Antibodies produced by the immune system against a therapeutic drug, which can affect its efficacy and safety.

References

  1. https://clinicaltrials.gov/study/NCT04586660
  2. https://clinicaltrials.gov/study/NCT04534582
  3. https://clinicaltrials.gov/study/NCT00306189
  4. https://clinicaltrials.gov/study/NCT00259740
  5. https://clinicaltrials.gov/study/NCT04812509
  6. https://clinicaltrials.gov/study/NCT01799798